Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Chief Financial Officer | January 02, 2026 | January 07, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Chief Financial Officer | February 21, 2023 | February 23, 2023 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | January 02, 2026 | January 06, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 87,081 |
Ending reported balance
After 2026-01-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 50,000 · Balance 94,704 F1: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2: Each RSU represents a contingent right to receive one ordinary share. Row 2 · 2026-01-02 · Sale · Disposed 3,289 · Balance 91,415 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (5) and (7). Row 3 · 2026-01-05 · Sale · Disposed 2,456 · Balance 88,959 F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive. Row 4 · 2026-01-05 · Sale · Disposed 1,878 · Balance 87,081 F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5237 to $6.5412 inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 100,000 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 100,000 · Balance 100,000 F8: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (5) and (7).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive.
F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5237 to $6.5412 inclusive.
F8: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter.
LENZ Therapeutics, Inc.
Report date February 21, 2023 · Filed February 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-02-20 | Direct | 220,000 |
Reported balance
After 2023-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-21 · Grant · Acquired 220,000 · Balance 220,000 F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date.
PTC THERAPEUTICS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,067 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 21,067 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01 | Direct | 3,475 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.
F2: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,798 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 17,798 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,891 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001628280-26-043006 · wk-form4_1781312840.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-043006 · wk-form4_1781312840.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,798 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,878 | $6.54 | $12,282.12 |
DisclosureSEC source: 0001918147-26-000004 · form4-01062026_080119.xml · nonDerivative · entry 4 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,081 F6 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5237 to $6.5412 inclusive. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 2,456 | $6.45 | $15,841.20 |
DisclosureSEC source: 0001918147-26-000004 · form4-01062026_080119.xml · nonDerivative · entry 3 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,959 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.30 to $6.70 inclusive. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001918147-26-000002 · form4-01062026_050114.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001918147-26-000002 · form4-01062026_050114.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,067 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001918147-26-000004 · form4-01062026_080119.xml · derivative · entry 5 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2036-01-02 F8 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2027 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 3,289 | $6.80 | $22,365.20 |
DisclosureSEC source: 0001918147-26-000004 · form4-01062026_080119.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,415 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.62 to $7.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4), (5) and (7). Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 01:00 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001918147-26-000004 · form4-01062026_080119.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,704 F1 · shares: Represents a restricted share unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2027 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 265 | $8.61 | $2,280.33 |
DisclosureSEC source: 0001918147-25-000004 · form4-10062025_041004.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,704 F3 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on April 3, 2025. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:45 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 217 | $8.40 | $1,822.80 |
DisclosureSEC source: 0001918147-25-000004 · form4-10062025_041004.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,969 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.37 to $8.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 21:20 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 204 | $7.09 | $1,446.36 |
DisclosureSEC source: 0001415889-25-019423 · form4-07072025_050701.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,186 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.09 to $7.14 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,279 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001396814-25-000081 · wk-form4_1749845846.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000081 · wk-form4_1749845846.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,393 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 21:35 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 215 | $8.02 | $1,724.30 |
DisclosureSEC source: 0001415889-25-010245 · form4-04042025_050410.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,390 F1 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of restricted stock units. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 8,800 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001029 · form4-01072025_050130.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001029 · form4-01072025_050130.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,067 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 87,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · derivative · entry 3 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: Ordinary Shares · 87,000 shares Expires 2035-01-02 F5 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on January 2, 2026 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | SaleOrdinary Shares | 1,395 | $14.09 | $19,655.55 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,605 F3 · kind: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.90 to $14.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:30 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000927 · form4-01062025_070126.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2026 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000076 · wk-form4_1718316787.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000076 · wk-form4_1718316787.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,230 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004101 · form4-02162024_040218.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004101 · form4-02162024_040218.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,067 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Stock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0001209191-24-000878 · doc4.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Ordinary Shares · 24,000 shares Expires 2034-01-02 F3 · derivative.exercise_date: This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 2, 2025 and the remaining shares in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:27 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantOrdinary Shares | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000878 · doc4.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F1 · shares: Represents a restricted stock unit ("RSU") award. One-fourth (1/4) of the total number of RSUs shall vest on January 2, 2025 and the remaining RSUs shall vest in 12 equal quarterly installments thereafter. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 20:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,967 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001396814-23-000073 · wk-form4_1697057217.xml · derivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,967 Underlying: Common Stock · 30,967 shares Expires 2033-10-06 F1 · derivative.exercise_date: The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $27.85 Strike: $27.85 | $129,948.10 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · derivative · entry 6 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,334 Underlying: Common Stock · 4,666 shares Expires 2032-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on June 9, 2022 and vests over thirty-six approximately equal monthly installments, commencing on July 8, 2022 Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $27.85 Strike: $27.85 | $194,950.00 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · derivative · entry 5 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2032-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,666 | $39.79 | $185,672.27 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · nonDerivative · entry 4 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,067 F1 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $39.77 to $39.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,666 | $27.85 | $129,948.10 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · nonDerivative · entry 3 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,000 | $39.90 | $279,300.00 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,067 Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,000 | $27.85 | $194,950.00 |
DisclosureSEC source: 0001415889-23-013116 · form4-09082023_080934.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 22:23 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | GrantEmployee Share Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $26.21 | $0.00 |
DisclosureSEC source: 0001209191-23-042789 · doc4.xml · derivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Ordinary Shares · 120,000 shares Expires 2033-07-17 F1 · derivative.exercise_date: This option shall vest with respect to one-fourth (1/4) of the total number of shares underlying the option on July 17, 2024 and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:04 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-23-012264 · doc4.xml · derivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:14 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000672 · form4-01092023_090114.xml · derivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:14 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000672 · form4-01092023_090114.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,067 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $27.85 | $0.00 |
DisclosureSEC source: 0001415889-22-006412 · form4-06102022_010627.xml · derivative · entry 4 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2032-06-08 F4 · derivative.exercise_date: This option was granted on June 9, 2022 and vests over seven approximately equal monthly installments, commencing on July 7, 2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $27.85 | $0.00 |
DisclosureSEC source: 0001415889-22-006412 · form4-06102022_010627.xml · derivative · entry 3 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-06-08 F3 · derivative.exercise_date: This option was granted on June 9, 2022 and vests over thirty-six approximately equal monthly installments, commencing on July 8, 2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 1,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006412 · form4-06102022_010627.xml · nonDerivative · entry 2 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,067 F2 · shares: Restricted stock units granted on June 9, 2022 that vest on January 7, 2023. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:08 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006412 · form4-06102022_010627.xml · nonDerivative · entry 1 Young Alethia · CIK 0001918147 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · shares: Restricted stock units granted on June 9, 2022 that vest in three equal installments over three years, commencing on June 8, 2023. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:01 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-22-023268 · doc4.xml · derivative · entry 1 Young Alethia · CIK 0001918147 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-03-31 F1 · derivative.exercise_date: 1/4th of the shares subject to such option will vest and become exercisable on April 1, 2023 and 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.